<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680005</article-id><article-id pub-id-type="doi">10.3390/vaccines12121376</article-id><article-id pub-id-type="publisher-id">vaccines-12-01376</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Post-Marketing Surveillance of Adverse Events for the Recombinant Zoster Vaccine Among the Population over 50 Years Old in Hangzhou, China</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6038-7559</contrib-id><name><surname>Wang</surname><given-names>Jing</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vaccines-12-01376" ref-type="aff">1</xref><xref rid="fn1-vaccines-12-01376" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Jian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af2-vaccines-12-01376" ref-type="aff">2</xref><xref rid="fn1-vaccines-12-01376" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-vaccines-12-01376" ref-type="aff">2</xref><xref rid="c1-vaccines-12-01376" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Yuyang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af2-vaccines-12-01376" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Jiayin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-vaccines-12-01376" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xuechao</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-vaccines-12-01376" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Maple</surname><given-names>Peter</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01376"><label>1</label>Department of Infectious Disease Control and Prevention, Hangzhou Center for Diseases Control and Prevention (Hangzhou Health Supervision Institution), Hangzhou 310021, China; <email>wangjing@hzcdc.com.cn</email></aff><aff id="af2-vaccines-12-01376"><label>2</label>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China; <email>dujian@hzcdc.com.cn</email> (J.D.); <email>xuyuyang@hzcdc.com.cn</email> (Y.X.); <email>hanjiayin@hzcdc.com.cn</email> (J.H.); <email>xchzhang@hzcdc.com.cn</email> (X.Z.)</aff><author-notes><corresp id="c1-vaccines-12-01376"><label>*</label>Correspondence: <email>liuyan@hzcdc.com.cn</email></corresp><fn id="fn1-vaccines-12-01376"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1376</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>04</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>05</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Objectives: This study aimed to evaluate the safety profile of the recombinant zoster vaccine (RZV) after its marketing in China. Methods: We present a descriptive analysis and safety signal assessment of adverse events following immunization (AEFI) associated with RZV between September 2020 and December 2023. The descriptive data collected includes demographic characteristics and the classification of characteristics of AEFI cases, while vaccine safety signal assessment was evaluated using the reporting odds ratio (ROR). Results: In total, we documented 275 AEFI cases following RZV vaccination, with a reporting rate of 76.22/10,000 doses administered. Notably, only one case was classified as serious, and the reporting rates were significantly higher among females, individuals aged 50&#x02013;59 years, and those residing in rural areas. Furthermore, the reporting rate for the first dose exceeded that for the second dose. Among the reported AEFI cases, 98.91% were attributed to vaccine product-related reactions, and 97.45% were initially reported by either the vaccine recipient or their guardians. The interval between vaccination and symptom onset was predominant within 3 d after vaccination. The disproportionality analysis identified five positive signals&#x02014;fever (37.5&#x02013;38.5 &#x000b0;C), injection site reactions greater than 5 cm, pain, Henoch Sch&#x000f6;nlein purpura (HSP), and swelling&#x02014;which suggests a stronger association with the RZV than the expected threshold. Conclusion: In summary, RZV demonstrated a favorable safety profile. However, continued monitoring and research on the long-term safety implications of RZV are needed.</p></abstract><kwd-group><kwd>adverse events following immunization</kwd><kwd>recombinant zoster vaccine</kwd><kwd>vaccine safety</kwd></kwd-group><funding-group><award-group><funding-source>Medical Science and Technology Project of Zhejiang Province</funding-source><award-id>2024KY233</award-id></award-group><funding-statement>This research was funded by the Medical Science and Technology Project of Zhejiang Province (grant number 2024KY233).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01376"><title>1. Introduction</title><p>Herpes zoster (HZ) is a neurological condition that primarily results from the reactivation of the varicella zoster virus. This virus remains dormant in the sensory ganglia of the host. However, in individuals with compromised immune systems, HZ is more likely to develop. Notably, individuals aged &#x02265;50 have an increased risk of developing postherpetic neuralgia (PHN) following HZ, with symptoms possibly persisting for several months [<xref rid="B1-vaccines-12-01376" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-12-01376" ref-type="bibr">2</xref>]. Findings from a systematic literature review of 69 studies revealed that the incidence of HZ ranges from 5.23 to 10.9 cases per 1000 person-years, with a higher prevalence observed in females than in males. Furthermore, the incidence of HZ notably increases with advancing age and over time [<xref rid="B3-vaccines-12-01376" ref-type="bibr">3</xref>], particularly for those with chronic underlying conditions [<xref rid="B4-vaccines-12-01376" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-01376" ref-type="bibr">5</xref>].</p><p>Vaccination is the primary strategy for preventing HZ [<xref rid="B6-vaccines-12-01376" ref-type="bibr">6</xref>]. Currently, there are two widely used HZ vaccines: the live zoster vaccine (ZVL) and recombinant zoster vaccine (RZV). The former was approved in 2006, whereas the latter received authorization for marketing only in 2017 in the USA [<xref rid="B7-vaccines-12-01376" ref-type="bibr">7</xref>]. Both vaccines have been shown to effectively reduce the incidence of HZ [<xref rid="B7-vaccines-12-01376" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01376" ref-type="bibr">8</xref>]. Furthermore, the efficacy of both vaccines in individuals aged &#x02265;50 was found to be 46% and 85%, respectively, based on findings from a retrospective analysis of real-world effectiveness data gathered over 10 years [<xref rid="B7-vaccines-12-01376" ref-type="bibr">7</xref>]. From a cost-effectiveness standpoint, the incremental cost-effectiveness ratios (ICERs) for RZV were higher than those for ZVL, with values ranging from USD 22,097 to USD 27,486 per quality-adjusted life year (QALY) in North America [<xref rid="B9-vaccines-12-01376" ref-type="bibr">9</xref>] and from USD 3428 to USD 5743 per QALY in China [<xref rid="B10-vaccines-12-01376" ref-type="bibr">10</xref>]. Additionally, various countries have incorporated RZV into their national immunization programs because it can be used for patients with compromised immune function and immune suppression, whereas ZVL is contraindicated in this population [<xref rid="B7-vaccines-12-01376" ref-type="bibr">7</xref>,<xref rid="B11-vaccines-12-01376" ref-type="bibr">11</xref>].</p><p>Nevertheless, in some countries, such as Saudi Arabia, RZV use among older adults remains relatively low, primarily because of the potential side effects associated with the vaccination [<xref rid="B4-vaccines-12-01376" ref-type="bibr">4</xref>]. Therefore, the adverse events following RZV vaccination have attracted substantial attention from the research community. A network meta-analysis of randomized controlled trials revealed that the association between adverse events and RZV was statistically stronger than that with ZVL or placebo [<xref rid="B12-vaccines-12-01376" ref-type="bibr">12</xref>]. Hence, the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) initiated the passive safety monitoring of the recombinant zoster vaccine after it was authorized for marketing in the United States. Furthermore, Hesse et al. 2019 conducted an observational study. They reported that the rate of adverse events associated with RZV was approximately 13.69 per 10,000 doses, with common signs and symptoms, such as fever and injection site reactions [<xref rid="B13-vaccines-12-01376" ref-type="bibr">13</xref>]. Their findings were consistent with those observed in premarketing clinical trials, with serious adverse events occurring in 3% of patients [<xref rid="B13-vaccines-12-01376" ref-type="bibr">13</xref>].</p><p>In addition, the RZV, developed by GlaxoSmithKline, was approved by the National Medical Products Administration of China in June 2020 for the prevention of shingles in adults aged &#x02265;50 years, priced at approximately USD 230 per dose [<xref rid="B14-vaccines-12-01376" ref-type="bibr">14</xref>]. Moreover, a Phase IV observer-blind study was conducted in China between 2021 and 2023. The results revealed that adverse reactions occurring within 7 d post-vaccination were significantly more frequent in the RZV group (76.3%) than in the placebo group (14.4%). However, the most commonly reported local and systemic adverse events were pain and fatigue [<xref rid="B15-vaccines-12-01376" ref-type="bibr">15</xref>].</p><p>Hangzhou, a city located in the southeastern region of China, is regarded as one of the country&#x02019;s most advanced cities in the country. Following the introduction of RZV in Hangzhou in September 2020, the increasing vaccination rate received considerable public attention due to the vaccine&#x02019;s relatively high cost and the particular characteristics of the demographic being targeted. Considering the limited safety monitoring data available for the RZV following its approval in China, we used data from the National Adverse Events Following Immunization (AEFI) Information System of China to systematically investigate AEFI associated with the RZV in Hangzhou over the past three years. We compared these findings with the reported AEFI associated with other vaccinations during the same period, aiming to evaluate the safety of RZV use among the target population in China and to explore the potential underlying factors.</p></sec><sec id="sec2-vaccines-12-01376"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-12-01376"><title>2.1. Data Source</title><p>Data were sourced from the Chinese National AEFI Information System (CNAEFIS), a passive surveillance system established for monitoring vaccine safety that has been in operation since 2008 [<xref rid="B16-vaccines-12-01376" ref-type="bibr">16</xref>]. All healthcare institutions, vaccination clinics, Centers for Disease Control and Prevention (CDC), vaccine manufacturers and distributors, and vaccine recipients (or their guardians) were responsible for reporting the incidence of AEFI cases that emerged after vaccination. The incidents and cases were systematically collected by the CDCs and reported to the CNAEFIS through an online platform. A specialized AEFI investigation team, made up of experts from clinical medicine, epidemiology, pharmacy, and adverse drug reactions (ADR), evaluated the causal relationship between these incidents and vaccination, classifying them according to the World Health Organization (WHO) manual [<xref rid="B17-vaccines-12-01376" ref-type="bibr">17</xref>]. The results of the evaluation and classification were also updated in CNAEFIS. Furthermore, data on zoster vaccine administration were sourced from a provincial immunization registration system, which was established in 2005 and operated on the internet.</p></sec><sec id="sec2dot2-vaccines-12-01376"><title>2.2. Data Extraction</title><p>Shingerix<sup>&#x000ae;</sup>, is a recombinant zoster vaccine that is approved for use in mainland China. It was produced by GlaxoSmithKline (GSK) located in Belgium. Its price is at approximately USD 230 per dose in China, and it is suitable for people for our target population. The immunization regimen comprised two doses (0.5 mL) initially, with the second dose administered two months after the first.</p><p>Data on recipients of the RZV extracted from the provincial immunization registration system comprised individuals vaccinated between 1 September 2020 and 31 December 2023. The AEFI reported during this period were retrieved from the CNAEFIS database based on the onset dates. The extracted data included demographic information (sex, age, and residential area), vaccination-related details (vaccination date, number of doses administered, onset date, reporting date, initial reporting source, the interval between vaccination and onset), and diagnostic information related to the AEFI cases (diagnosis classification by cause-specific criteria and severity).</p></sec><sec id="sec2dot3-vaccines-12-01376"><title>2.3. Data Analysis</title><p>The database was systematically compiled and organized using Microsoft Excel (2019), and the data were analyzed using chi-square utilizing the Statistical Package for Social Sciences (SPSS, Version 22.0). We categorized the cases by age based on global clinical studies on adverse reactions outlined in the vaccine&#x02019;s instructions for use. Additionally, we classified cases according to the time interval from vaccination to symptom onset, following China&#x02019;s national AEFI guidelines.</p><p>Descriptive statistics included the analysis of the temporal distribution (by month), residential area (categorized into urban, suburban, and rural areas), sex (sorted by three age groups), dose number, cause-specific classification, initial reporting source, and time interval of AEFI occurrence. We calculated the AEFI reporting rate for each variable as the total number of AEFIs reported for that variable during the study period divided by the total number of doses administered for that variable and expressed per 10,000 doses. Quantitative data were presented as numerical values and/or rates, and the differences were analyzed using the chi-square test. Differences in sex after classification were analyzed using stratified chi-square test. Statistical significance was set at <italic toggle="yes">p</italic> &#x0003c; 0.05.</p><p>We used the disproportionality analysis approach to detect concerns of potential vaccine safety in this study. This method flags a safety signal when the observed link between a specific vaccine and a diagnosis exceeds the expected threshold, which indicates a disproportionate relationship. We used the reporting odds ratio (ROR) as our analytical tool, and a signal was considered positive if the lower limit of the 95% confidence interval (CI) for the ROR was greater than one [<xref rid="B18-vaccines-12-01376" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-12-01376" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01376" ref-type="bibr">20</xref>]. None of the cases reported in this study had records of simultaneous administration of multiple vaccines. However, only the primary diagnosis was used in this report, considering that patients with AEFI may present with multiple concurrent diagnoses.</p></sec><sec id="sec2dot4-vaccines-12-01376"><title>2.4. Study Ethics</title><p>The research was performed following the principles of the Declaration of Helsinki (1964) and was approved by the Ethics Committee at the Hangzhou Center for Disease Control and Prevention (protocol numbers 2023-KS10, dated 8 December 2023). All data used in the analysis had no personal identifiers, ensuring that only anonymized data were used.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01376"><title>3. Results</title><sec id="sec3dot1-vaccines-12-01376"><title>3.1. Descriptive Results</title><p>Since the recombinant zoster vaccine was first administered in Hangzhou, China, in September 2020, approximately 36,079 doses have been administered to the entire city as of 31 December 2023, with an average of 902.0 doses administered per month. Excluding the first month, during which no AEFI cases were reported, monthly reports of AEFI associated with the RZV were recorded for the subsequent 39 months, totaling 275 cases and with a reporting rate of 76.22 per 10,000 doses. Of these cases, only one serious AEFI was reported in November 2023, with a serious AEFI reporting rate of 0.28 per 10,000 doses. The remaining 274 patients had nonserious diseases. Furthermore, the number of RZV vaccinations showed a steady annual increase between 2020 and 2023. This increase culminated in 2023, with 14,759 doses administered across the city. Concurrently, the number of AEFI reports increased, rising from 18 cases in 2020 to 123 cases in 2023; however, the reporting rate did not significantly differ over the four-year period (&#x003c7;<sup>2</sup> = 5.10 <italic toggle="yes">p</italic> = 0.17) (<xref rid="vaccines-12-01376-t001" ref-type="table">Table 1</xref> and <xref rid="vaccines-12-01376-f001" ref-type="fig">Figure 1</xref>).</p><p>All vaccine recipients were aged &#x02265;50 years, with the 50&#x02013;59 age group receiving the highest number of doses (19,208 doses). Approximately 170 AEFI cases were reported in this group, with a reporting rate of 88.50 per 10,000 doses. This rate was also the highest among the three age groups. The number of vaccinations administered to the subsequent age group (60&#x02013;69 years) decreased to 13,198 doses, with 86 reported AEFI, which resulted in a reporting rate of 65.16 per 10,000 doses. Those in the &#x02265;70 years age group showed the lowest numbers in terms of vaccine doses, AEFI cases, and reporting rates. The reported numbers reported in this group declined to 3673 doses, 19 cases, and 51.73 per 10,000 doses. Notably, the three age groups significantly differed (&#x003c7;<sup>2</sup> = 8.88 <italic toggle="yes">p</italic> &#x0003c; 0.05). Upon stratification by age groups, we discovered that the reporting rate of AEFI was highest among women aged 50&#x02013;59, and the lowest among men aged &#x02265;70 years. The vaccination and reporting rate of AEFI were both higher among women in all three age groups than in men. Through stratified chi-square analysis, a statistically significant difference in AEFI incidence was observed between men and women (&#x003c7;<sup>2</sup> = 14.13, <italic toggle="yes">p</italic> &#x0003c; 0.05). Furthermore, the first and second doses administered were relatively comparable, which were 19,790 and 16,289 doses, respectively, indicating that the majority of individuals were fully vaccinated. However, the numbers of AEFI associated with the two doses significantly differed, with 168 cases reported for the former (reporting rate of 106.62 per 10,000 doses) and only 87 cases for the latter (reporting rate of 39.29 per 10,000 doses) (&#x003c7;<sup>2</sup> = 53.55 <italic toggle="yes">p</italic> &#x0003c; 0.05).</p><p>In terms of geographical distribution, the Central City recorded the highest number of varicella vaccine doses administered (23,626) and concurrently reported the highest number of varicella vaccine-related AEFI cases (191). However, those in the suburbs received 9231 doses, resulting in 39 reported cases of AEFI, whereas rural areas received the fewest doses during the study period (3222), with a total of 45 reported AEFI cases. On the other hand, with respect to AEFI reporting rates, remote areas had the highest rate (139.66 per 10,000 doses), followed by central urban areas (80.84 per 10,000 doses), with near central urban areas recording the lowest rate (42.25 per 10,000 doses). The vaccination rates significantly differed among these three areas (&#x003c7;<sup>2</sup> = 20.28 <italic toggle="yes">p</italic> &#x0003c; 0.05).</p><p>Following vaccination, 98.91% of the AEFI cases were classified by the diagnostic panel as vaccine product-related reactions (272 cases), which included one case of a serious reaction, representing 98.91% of the total. Furthermore, these three cases were classified as coincidental events. Most of the initial reports (268; 97.45%) originated from the vaccine recipients themselves or their guardians, whereas only seven cases were reported by vaccination clinics. Regarding the time interval of AEFI occurrence, 257 cases (93.45%) occurred within 24 h post-vaccination, whereas 11 cases (4.00%) were reported within 2&#x02013;3 days after vaccination. However, only seven cases (2.55%) occurred beyond 4 d after vaccination (<xref rid="vaccines-12-01376-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec3dot2-vaccines-12-01376"><title>3.2. Clinical Diagnosis</title><p><xref rid="vaccines-12-01376-t003" ref-type="table">Table 3</xref> shows 275 AEFI cases reported after receiving the RZV. Among them, 274 cases were mild vaccine-related reactions. Based on the diagnostic results, fever was the most reported diagnosis, accounting for 162 cases (58.91%). Among these cases, those with a temperature ranging from 37.5&#x02013;38.5 &#x000b0;C (123 cases, 34.09 per 10,000 doses) were markedly higher than those having &#x02265;38.5 &#x000b0;C (39 cases, 10.81 per 10,000 doses). The second most commonly reported diagnosis was an injection site reaction, characterized by redness, swelling, and induration at the injection site, observed in 83 cases (30.18%). This reaction was divided into three grades based on the size of the affected area, which was ranked based on the number of cases: 2.6&#x02013;5.0 cm (45 cases), &#x0003e;5.0 cm (27 cases), and &#x02264;2.5 cm (11 cases). There were nine cases of fatigue and six cases of pain, of which one was classified as coincidental. Furthermore, there were four cases of allergic rash and three cases of other types of rashes, of which one was classified as coincidental. Additionally, gastrointestinal reactions, swelling, and neurological reactions were each observed in two instances of AEFI after vaccination. Only a single case of cardiovascular disease was reported; however, this case was subsequently determined by the expert panel to be coincidental. The only case of a serious vaccine-related reaction diagnosed was Henoch&#x02013;Sch&#x000f6;nlein purpura (HSP).</p><p>From the positive signals, the following were identified: fever ranging from 37.5 &#x000b0;C to 38.5 &#x000b0;C (ROR-1.96, SE: 6.09), swelling (ROR-1.96, SE: 5.02), HSP (ROR-1.96, SE: 2.73), reaction at the injection site (&#x0003e;5.0 cm) (ROR-1.96, SE: 2.57), and pain (ROR-1.96, SE: 1.86).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01376"><title>4. Discussion</title><p>RZV is specifically formulated for adults aged &#x02265;50 years to prevent shingles and its associated complications. This vaccine stimulates the human immune system to generate antibodies, thereby achieving its preventive objective [<xref rid="B7-vaccines-12-01376" ref-type="bibr">7</xref>]. It was launched in China in 2020 and has substantially contributed to making shingle vaccination available for our target population, with an increasing acceptance rate observed annually. However, all vaccinations carry inherent risks, including local and systemic reactions. The occurrence of AEFI impacts the health of recipients and may also adversely affect immunization programs. Therefore, the timely and accurate monitoring and evaluation of AEFI associated with RZV are necessary to maintain public confidence and ensure the success of immunization initiatives.</p><p>An analysis of RZV-associated adverse events reported in the NAEFISS system revealed that the reporting rate of AEFI for the RZV in Hangzhou was 72 per 10,000 doses. Moreover, RZV has been available in the market for over 3 years, and this rate is significantly higher than both the reporting rate documented by GSK (16.82) [<xref rid="B21-vaccines-12-01376" ref-type="bibr">21</xref>] and the passive monitoring results from the United States 2 years after the vaccine was launched (13.69 per 10,000 doses) [<xref rid="B13-vaccines-12-01376" ref-type="bibr">13</xref>]. Furthermore, when compared with existing research findings within China, the AEFI reporting rate following RZV vaccination in Hangzhou was considerably greater than that observed by Bo et al. 2022 in Guangdong Province 1 year after the vaccine was introduced (19.67 per 10,000 doses) [<xref rid="B14-vaccines-12-01376" ref-type="bibr">14</xref>]. The Weber effect may explain the elevated reporting rate observed. The Weber effect posits that the incidence of reported adverse events tends to increase shortly after a drug&#x02019;s approval before gradually stabilizing [<xref rid="B19-vaccines-12-01376" ref-type="bibr">19</xref>]. In addition, it is important to consider the influence of large-scale COVID-19 vaccination campaigns conducted between 2020 and 2023 because these campaigns may have significantly heightened public awareness regarding adverse reactions following vaccination [<xref rid="B22-vaccines-12-01376" ref-type="bibr">22</xref>].</p><p>The demographic information of the population reporting RZV-related adverse event reports indicated that there was a significant age group disparity in the reporting rate of AEFI, with the highest rate occurring in the 50&#x02013;59 age group, aligning with the findings of Ramona&#x02019;s team and Tavares-Da-Silva&#x02019;s team [<xref rid="B11-vaccines-12-01376" ref-type="bibr">11</xref>,<xref rid="B21-vaccines-12-01376" ref-type="bibr">21</xref>]. This difference was also observed in vulnerable populations [<xref rid="B23-vaccines-12-01376" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01376" ref-type="bibr">24</xref>]. After sex was sorted by different age groups, we discovered that the sensitivity of females to adverse events was higher than that of males in all age groups, including 50&#x02013;59, 60&#x02013;69, and &#x02265;70 years. Similar outcomes were also reported in a review of adverse reactions to COVID-19 vaccines [<xref rid="B25-vaccines-12-01376" ref-type="bibr">25</xref>]. However, reporting bias between sex and age groups may have influenced this result. Additionally, the results may be attributed to the biological distinctions between males and females, including hormones, genes, and past exposure history [<xref rid="B26-vaccines-12-01376" ref-type="bibr">26</xref>]. Moreover, disparities in the AEFI reporting rates were observed across different residential areas, with rural areas showing the highest rates. This phenomenon may be attributed to the lower level of vaccine knowledge among older adults in these areas and their insufficient confidence in vaccine safety [<xref rid="B27-vaccines-12-01376" ref-type="bibr">27</xref>].</p><p>The findings of this study reveal that the reporting rate of AEFIs after the first dose was higher than that following the second dose, with the majority of AEFIs occurring within 0&#x02013;1 d post-vaccination. This observation aligns with the results reported in Australia and Guangdong Province of China, after the introduction of the vaccine [<xref rid="B11-vaccines-12-01376" ref-type="bibr">11</xref>,<xref rid="B14-vaccines-12-01376" ref-type="bibr">14</xref>]. However, the two doses did not significantly differ in clinical trials involving immunocompetent adults aged &#x02265;50 years across 18 countries, including those in Europe, Latin America, and the Asia-Pacific region [<xref rid="B28-vaccines-12-01376" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-12-01376" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-12-01376" ref-type="bibr">30</xref>]. Notably, the difference between the two, in the real world, may be due to the fact that recipients of the first dose paid more attention to adverse reactions and hence reported higher rates of occurrence and that recipients who experienced adverse reactions after the first dose did not receive the second dose. However, in frail populations, researchers have found that medications were used more often for treatment after the second dose than after the first (28% vs. 13%) [<xref rid="B23-vaccines-12-01376" ref-type="bibr">23</xref>]. Regarding the time interval from vaccination to the onset of AEFI, a significant majority of AEFIs occurred within 3 days (97.45%), which aligns with the post-marketing surveillance findings in the United States and Europe [<xref rid="B13-vaccines-12-01376" ref-type="bibr">13</xref>,<xref rid="B21-vaccines-12-01376" ref-type="bibr">21</xref>]. A plausible explanation for this observation is that the interval between vaccination and the most frequently reported AEFIs (such as fever or injection site reactions) is relatively brief because the observation may arise from local inflammation or dysregulation of central temperature control [<xref rid="B19-vaccines-12-01376" ref-type="bibr">19</xref>]. Seven cases showed an onset time and interval exceeding 4 d, which were all generally mild reactions (primarily rashes and pain, among others). These onset times were influenced by the considerable time spent between reporting and vaccination, resulting in some recall bias. There was one case that occurred in which a rash was caused by other reasons but not associated with vaccination. After discussion by the AEFI diagnostic panel, this event was categorized as a coincidence. Similar findings of delayed skin rashes were reported in studies on adverse reactions following COVID-19 vaccination, where T-cell-mediated hypersensitivity plays a major role in the pathogenesis of these skin lesions [<xref rid="B25-vaccines-12-01376" ref-type="bibr">25</xref>], suggesting that these reactions are neither novel nor unidentified safety concerns of vaccination.</p><p>In addition, our study revealed a notable finding that most of the initial sources of report (97.45%) were vaccine recipients or guardians. This indicates that most reported AEFI cases are not immediate post-vaccination events; rather, they are identified and reported by the recipients or guardians after returning home. However, only seven cases (1.94%) occurred during the post-vaccination observation period. These cases were documented in the vaccination clinic&#x02019;s reporting system. These findings suggest that serious anaphylactic reactions (such as anaphylactic shock and laryngeal edema) are exceedingly rare following RZV vaccination.</p><p>In our study, the most frequently diagnosed AEFI was fever (162 cases, 58.91%), with suspected positive signals observed for mild to moderate fever ranging from 37.5 to 38.5 &#x000b0;C, indicating that this symptom showed a higher reporting rate than the average levels of other vaccines administered during the study period [<xref rid="B13-vaccines-12-01376" ref-type="bibr">13</xref>,<xref rid="B21-vaccines-12-01376" ref-type="bibr">21</xref>]. Another commonly reported positive signal was a large injection site reaction, primarily characterized by redness and induration exceeding 5 cm in diameter. This finding aligns with results from a study published in the New England Journal of Medicine [<xref rid="B28-vaccines-12-01376" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-12-01376" ref-type="bibr">29</xref>]. They reported that approximately 17% of participants had erythema and induration &#x0003e; 3.5 inches, which was typically self-limiting; however, it resolved within several days [<xref rid="B13-vaccines-12-01376" ref-type="bibr">13</xref>]. The reaction at the injection site could have resulted from the stimulation of nociceptive sensory neurons during vaccination or by a subsequent inflammatory process in the damaged tissue [<xref rid="B19-vaccines-12-01376" ref-type="bibr">19</xref>]. Pain, the third positive signal in this study, has also been mentioned in multiple research findings [<xref rid="B15-vaccines-12-01376" ref-type="bibr">15</xref>,<xref rid="B23-vaccines-12-01376" ref-type="bibr">23</xref>]. Moreover, the AS01<sub>b</sub> adjuvant may significantly influence these three symptoms [<xref rid="B31-vaccines-12-01376" ref-type="bibr">31</xref>]. The reported incidence of local and systemic adverse reactions associated with RZV was notably higher than that of other traditional vaccines such as hepatitis B and influenza vaccines. This increased incidence may be a result of the use of the patented AS01<sub>b</sub> adjuvant in the Shingrix HZ vaccine, which is a liposome-based complex adjuvant system containing two immune stimulants: monophosphoryl rapid A and saponin QS21 [<xref rid="B14-vaccines-12-01376" ref-type="bibr">14</xref>]. This adjuvant system can simultaneously induce robust humoral and cellular immune responses in the host [<xref rid="B32-vaccines-12-01376" ref-type="bibr">32</xref>]. Furthermore, research indicates that AS01 is rapidly distributed to the muscle and lymph nodes within 30 min after intramuscular injection, prompting a swift influx of neutrophils, monocytes, dendritic cells (DCs), and T cell populations into both the injection site and the lymph nodes [<xref rid="B33-vaccines-12-01376" ref-type="bibr">33</xref>]. Consequently, this novel adjuvant enhances immunogenicity and results in more frequent general reactions [<xref rid="B7-vaccines-12-01376" ref-type="bibr">7</xref>,<xref rid="B31-vaccines-12-01376" ref-type="bibr">31</xref>].</p><p>Two additional positive signals were identified during the diagnosis of HSP and swelling. HSP is a systemic vasculitis resulting from a hypersensitivity reaction that affects small blood vessels. Notably, vaccine-associated cases are relatively rare [<xref rid="B31-vaccines-12-01376" ref-type="bibr">31</xref>]. In this study, only one case of HSP associated with vaccination was reported, which was classified as a severe case following the WHO Health Organization criteria because of the necessity for hospitalization [<xref rid="B17-vaccines-12-01376" ref-type="bibr">17</xref>]. Instances of HSP events have been documented following vaccinations against influenza, hepatitis B, and COVID-19 [<xref rid="B34-vaccines-12-01376" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-12-01376" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-12-01376" ref-type="bibr">36</xref>]. However, its cause remains unclear, potentially caused by vaccine antigens also attacking human proteins with similar structures through molecular mimicry, hence leading to an autoimmune disease. It may also be due to adjuvants in the vaccine binding to pattern recognition receptors, recruiting natural immune cells, and secreting large amounts of cytokines to induce innate immune responses [<xref rid="B37-vaccines-12-01376" ref-type="bibr">37</xref>]. However, based on the research findings of The Brighton Collaboration Fever Working Group, HSP primarily occurs in children aged 1&#x02013;17, with fewer cases in older individuals (&#x0003e;65 years) [<xref rid="B38-vaccines-12-01376" ref-type="bibr">38</xref>]; therefore, the occurrence of this abnormal reaction after RZV vaccination requires more attention. We also identified two cases of swelling that occurred post-vaccination. This swelling was not at the injection site but in the facial region or lower limbs, which differs from the injection site swelling reported in studies conducted in the United States and Australia and is presumed to result from allergic reactions leading to increased vascular permeability, which allows fluid from the bloodstream to infiltrate the surrounding tissues. However, the precise etiology of this condition needs further investigation.</p><p>This study also has some limitations. First, data were obtained using a passive AEFI surveillance system. Furthermore, the surveillance systems themselves have some inherent limitations; for example, reporters may not report all adverse events due to concerns or may over-report certain reactions due to high attention to the new vaccine. Additionally, the lack of information regarding the recipient&#x02019;s medical history, current illness, and medication use makes it difficult to determine the true incidence of adverse events. In this case, the passive AEFI surveillance system can only assess potential risks based on case data and provide suspicious safety signals. However, these initially identified signals still need to be verified and confirmed through further research to ensure the accuracy and reliability of the results.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01376"><title>5. Conclusions</title><p>Based on our surveillance data between September 2020 and December 2023, increased scrutiny may have caused a high reporting rate of AEFI for the newly introduced recombinant varicella vaccine; however, it has an overall good tolerability among individuals aged &#x02265;50 years in China, with only one case of severe HSP documented. Therefore, continued vigilance and research are essential to assess the long-term safety of this vaccine among older adults who are Chinese.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors express their gratitude to all personnel working on disease control and prevention at all vaccination clinics, CDCs, and other medical institutions in Hangzhou, China.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: J.D. and J.W.; methodology: J.W. and Y.L.; software: J.W.; validation: J.D. and Y.X.; formal analysis: J.W.; investigation: J.H. and X.Z.; resources: J.D.; data curation: J.D. and J.W.; writing&#x02014;original draft preparation: J.W.; writing&#x02014;review and editing: Y.L.; visualization: J.W.; supervision: Y.L.; project administration: Y.L.; funding acquisition: J.W. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The research was carried out following the principles of the Declaration of Helsinki (1964) and received approval from the Ethics Committee at the Hangzhou Center for Disease Control and Prevention (protocol numbers 2023-KS10, dated 8 December 2023).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all participants involved in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data were unavailable because of privacy or ethical restrictions.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01376"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Bunge</surname><given-names>E.</given-names></name>
</person-group><article-title>Epidemiology and immunization strategy of herpes zoster</article-title><source>Chronic Pathematol. J.</source><year>2021</year><volume>22</volume><fpage>1145</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.16440/J.CNKI.1674-8166.2021.08.01</pub-id></element-citation></ref><ref id="B2-vaccines-12-01376"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Ren</surname><given-names>H.</given-names></name>
</person-group><article-title>Viral infectious disease</article-title><source>Infectetious Diseases</source><edition>9th ed.</edition><person-group person-group-type="editor">
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Ren</surname><given-names>H.</given-names></name>
</person-group><publisher-name>People&#x02019;s Medical Publishing House</publisher-name><publisher-loc>Beijing, China</publisher-loc><year>2018</year><volume>Volume 1</volume><fpage>88</fpage><lpage>89</lpage></element-citation></ref><ref id="B3-vaccines-12-01376"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Oorschot</surname><given-names>D.</given-names></name>
<name><surname>Vroling</surname><given-names>H.</given-names></name>
<name><surname>Bunge</surname><given-names>E.</given-names></name>
<name><surname>Diaz-Decaro</surname><given-names>J.</given-names></name>
<name><surname>Curran</surname><given-names>D.</given-names></name>
<name><surname>Yawn</surname><given-names>B.</given-names></name>
</person-group><article-title>A systematic literature review of herpes zoster incidence worldwide</article-title><source>Hum. Vaccines Immunother.</source><year>2021</year><volume>17</volume><fpage>1714</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1847582</pub-id><pub-id pub-id-type="pmid">33651654</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01376"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almakhdob</surname><given-names>M.</given-names></name>
<name><surname>Selim</surname><given-names>M.</given-names></name>
<name><surname>Abdalrouf</surname><given-names>A.</given-names></name>
</person-group><article-title>Factors Influencing Herpes Zoster Vaccine Utilization Among Adults Aged 50 and Above Attending Primary Healthcare Center in Saudi Arabia: A Cross-Sectional Study</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e66761</fpage><pub-id pub-id-type="doi">10.7759/cureus.66761</pub-id><pub-id pub-id-type="pmid">39280450</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01376"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Shin</surname><given-names>J.</given-names></name>
<name><surname>Bea</surname><given-names>S.</given-names></name>
<name><surname>Ye</surname><given-names>B.</given-names></name>
<name><surname>Lee</surname><given-names>D.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Choi</surname><given-names>W.</given-names></name>
<name><surname>Shantakumar</surname><given-names>S.</given-names></name>
</person-group><article-title>Burden of Herpes Zoster in Individuals with Chronic Conditions in the Republic of Korea: A Nationwide Population-Based Database Study</article-title><source>Open Forum Infect. Dis.</source><year>2024</year><volume>11</volume><fpage>ofae535</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofae535</pub-id><pub-id pub-id-type="pmid">39355262</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01376"><label>6.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Varicella and Herpes Zoster Vaccines: WHO Position Paper. June 2014</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/i/item/who-wer-8925-265-288" ext-link-type="uri">https://www.who.int/publications/i/item/who-wer-8925-265-288</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-29">(accessed on 29 September 2024)</date-in-citation></element-citation></ref><ref id="B7-vaccines-12-01376"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marra</surname><given-names>Y.</given-names></name>
<name><surname>Lalji</surname><given-names>F.</given-names></name>
</person-group><article-title>Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>2667</elocation-id><pub-id pub-id-type="doi">10.3390/v14122667</pub-id><pub-id pub-id-type="pmid">36560671</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01376"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deng</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
</person-group><article-title>Epidemiological Characteristics of Herpes Zoster and Research Progress of Vaccine Immunization Program in China</article-title><source>China Contin. Med. Educ.</source><year>2021</year><volume>13</volume><fpage>135</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.3969/j.issn.1674-9308.2021.19.039</pub-id></element-citation></ref><ref id="B9-vaccines-12-01376"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>George</surname><given-names>S.</given-names></name>
<name><surname>Carrico</surname><given-names>J.</given-names></name>
<name><surname>Hicks</surname><given-names>K.</given-names></name>
<name><surname>Loukov</surname><given-names>D.</given-names></name>
<name><surname>Ng</surname><given-names>C.</given-names></name>
<name><surname>Regan</surname><given-names>J.</given-names></name>
<name><surname>Giannelos</surname><given-names>N.</given-names></name>
</person-group><article-title>Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older</article-title><source>Pharmacoecon. Open</source><year>2024</year><volume>8</volume><fpage>785</fpage><pub-id pub-id-type="doi">10.1007/s41669-024-00502-w</pub-id><pub-id pub-id-type="pmid">39017906</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01376"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Jin</surname><given-names>P.</given-names></name>
<name><surname>Jin</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Zhu</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated Vaccine</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>872</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12080872</pub-id><pub-id pub-id-type="pmid">39203998</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01376"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muttucumaru</surname><given-names>R.</given-names></name>
<name><surname>Lau</surname><given-names>C.</given-names></name>
<name><surname>Leeb</surname><given-names>A.</given-names></name>
<name><surname>Mills</surname><given-names>D.</given-names></name>
<name><surname>Wood</surname><given-names>N.</given-names></name>
<name><surname>Furuya-Kanamori</surname><given-names>L.</given-names></name>
</person-group><article-title>Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>3166</fpage><lpage>3171</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.03.066</pub-id><pub-id pub-id-type="pmid">38677792</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01376"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tricco</surname><given-names>A.</given-names></name>
<name><surname>Zarin</surname><given-names>W.</given-names></name>
<name><surname>Cardoso</surname><given-names>R.</given-names></name>
<name><surname>Veroniki</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>P.</given-names></name>
<name><surname>Nincic</surname><given-names>V.</given-names></name>
<name><surname>Ghassemi</surname><given-names>M.</given-names></name>
<name><surname>Warren</surname><given-names>R.</given-names></name>
<name><surname>Sharpe</surname><given-names>J.</given-names></name>
<name><surname>Page</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: Systematic review and network meta-analysis</article-title><source>Br. Med. J.</source><year>2018</year><volume>363</volume><fpage>k4029</fpage><pub-id pub-id-type="doi">10.1136/bmj.k4029</pub-id><pub-id pub-id-type="pmid">30361202</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01376"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hesse</surname><given-names>E.</given-names></name>
<name><surname>Shimabukuro</surname><given-names>T.</given-names></name>
<name><surname>Su</surname><given-names>J.</given-names></name>
<name><surname>Hibbs</surname><given-names>B.</given-names></name>
<name><surname>Dooling</surname><given-names>K.</given-names></name>
<name><surname>Goud</surname><given-names>R.</given-names></name>
<name><surname>Lewis</surname><given-names>P.</given-names></name>
<name><surname>Ng</surname><given-names>C.</given-names></name>
<name><surname>Cano</surname><given-names>M.</given-names></name>
</person-group><article-title>Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix)&#x02014;United States, October 2017&#x02013;June 2018</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2019</year><volume>68</volume><fpage>91</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6804a4</pub-id><pub-id pub-id-type="pmid">30703077</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01376"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bo</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Liang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>P.</given-names></name>
</person-group><article-title>A Comprehensive Analysis of Suspected Adverse Reactions Following Shingles Vaccination in Guangdong Province, China (2020&#x02013;2021)</article-title><source>South China J. Prev. Med.</source><year>2022</year><volume>48</volume><fpage>592</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.12183/j.scjpm.2022.0592</pub-id></element-citation></ref><ref id="B15-vaccines-12-01376"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Proano</surname><given-names>D.</given-names></name>
<name><surname>Zhu</surname><given-names>F.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Zoco</surname><given-names>J.</given-names></name>
<name><surname>Soni</surname><given-names>J.</given-names></name>
<name><surname>Parmar</surname><given-names>N.</given-names></name>
<name><surname>Ali</surname><given-names>S.</given-names></name>
</person-group><article-title>Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults &#x02265; 50 years: A randomized, placebo-controlled trial</article-title><source>Hum. Vaccines Immunother.</source><year>2024</year><volume>20</volume><fpage>2351584</fpage><pub-id pub-id-type="doi">10.1080/21645515.2024.2351584</pub-id></element-citation></ref><ref id="B16-vaccines-12-01376"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Xu</surname><given-names>D.</given-names></name>
<name><surname>Ye</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
</person-group><article-title>Surveillance of adverse events following immunization in China: Past, present, and future</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4041</fpage><lpage>4046</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.060</pub-id><pub-id pub-id-type="pmid">25936727</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01376"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Causality Assessment of an Adverse Event Following Immunization (AEFI): User Manual for the Revised WHO Classification</source><edition>2nd ed.</edition><comment>2019 Update</comment><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2021</year><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/i/item/9789241516990" ext-link-type="uri">https://www.who.int/publications/i/item/9789241516990</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-24">(accessed on 24 September 2024)</date-in-citation></element-citation></ref><ref id="B18-vaccines-12-01376"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
</person-group><article-title>Systematic Review of Applications of Data Mining Algorithms for Vaccine Safety Signal Detection</article-title><source>Chin. J. Vaccines Immun.</source><year>2014</year><volume>20</volume><fpage>556</fpage><lpage>558</lpage></element-citation></ref><ref id="B19-vaccines-12-01376"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Liang</surname><given-names>H.</given-names></name>
<name><surname>Shen</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Lv</surname><given-names>H.</given-names></name>
</person-group><article-title>Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China</article-title><source>Hum. Vaccines Immunother.</source><year>2022</year><volume>18</volume><fpage>2035141</fpage><pub-id pub-id-type="doi">10.1080/21645515.2022.2035141</pub-id></element-citation></ref><ref id="B20-vaccines-12-01376"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Du</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Che</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Han</surname><given-names>J.</given-names></name>
</person-group><article-title>Analysis of Adverse Events Post-13-Valent Pneumococcal Vaccination among Children in Hangzhou, China</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>576</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12060576</pub-id><pub-id pub-id-type="pmid">38932305</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01376"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tavares-Da-Silva</surname><given-names>F.</given-names></name>
<name><surname>Co</surname><given-names>M.</given-names></name>
<name><surname>Dessart</surname><given-names>C.</given-names></name>
<name><surname>Herv&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>L&#x000f3;pez-Fauqued</surname><given-names>M.</given-names></name>
<name><surname>Mahaux</surname><given-names>O.</given-names></name>
<name><surname>Van Holle</surname><given-names>L.</given-names></name>
<name><surname>Stegmann</surname><given-names>J.-U.</given-names></name>
</person-group><article-title>Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>3489</fpage><lpage>3500</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.11.058</pub-id><pub-id pub-id-type="pmid">31818534</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01376"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheong</surname><given-names>D.L.S.</given-names></name>
<name><surname>Tran</surname><given-names>J.</given-names></name>
<name><surname>Chong</surname><given-names>W.</given-names></name>
<name><surname>May</surname><given-names>S.</given-names></name>
<name><surname>Carlson</surname><given-names>S.</given-names></name>
<name><surname>Salter</surname><given-names>S.</given-names></name>
<name><surname>Attwell</surname><given-names>K.</given-names></name>
</person-group><article-title>Attitudes, perceptions, and experiences of Western Australians towards vaccine safety surveillance systems following COVID-19 vaccines: A qualitative descriptive study</article-title><source>Aust. N. Z. J. Public Health</source><year>2024</year><volume>48</volume><fpage>100177</fpage><pub-id pub-id-type="doi">10.1016/j.anzjph.2024.100177</pub-id><pub-id pub-id-type="pmid">39029385</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01376"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costantino</surname><given-names>M.</given-names></name>
<name><surname>Giudice</surname><given-names>V.A.-O.</given-names></name>
<name><surname>Moccia</surname><given-names>G.A.-O.</given-names></name>
<name><surname>Longanella</surname><given-names>W.</given-names></name>
<name><surname>Caruccio</surname><given-names>S.</given-names></name>
<name><surname>Tremiterra</surname><given-names>G.</given-names></name>
<name><surname>Sinopoli</surname><given-names>P.</given-names></name>
<name><surname>Benvenuto</surname><given-names>D.</given-names></name>
<name><surname>Serio</surname><given-names>B.</given-names></name>
<name><surname>Malatesta</surname><given-names>F.A.-O.</given-names></name>
<etal/>
</person-group><article-title>Safety of Adjuvanted Recombinant Herpes Zoster Virus Vaccination in Fragile Populations: An Observational Real-Life Study</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>990</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12090990</pub-id><pub-id pub-id-type="pmid">39340022</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01376"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stefanizzi</surname><given-names>P.</given-names></name>
<name><surname>Moscara</surname><given-names>L.</given-names></name>
<name><surname>Palmieri</surname><given-names>C.</given-names></name>
<name><surname>Martinelli</surname><given-names>A.</given-names></name>
<name><surname>Di Lorenzo</surname><given-names>A.</given-names></name>
<name><surname>Venerito</surname><given-names>V.</given-names></name>
<name><surname>Germinario</surname><given-names>C.A.</given-names></name>
<name><surname>Tafuri</surname><given-names>S.</given-names></name>
</person-group><article-title>Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021&#x02013;2023</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>2966</fpage><lpage>2974</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.03.024</pub-id><pub-id pub-id-type="pmid">38582693</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01376"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qaderi</surname><given-names>K.</given-names></name>
<name><surname>Golezar</surname><given-names>M.H.</given-names></name>
<name><surname>Mardani</surname><given-names>A.</given-names></name>
<name><surname>Mallah</surname><given-names>M.A.-O.</given-names></name>
<name><surname>Moradi</surname><given-names>B.A.-O.</given-names></name>
<name><surname>Kavoussi</surname><given-names>H.</given-names></name>
<name><surname>Shamsabadi</surname><given-names>A.</given-names></name>
<name><surname>Golezar</surname><given-names>S.</given-names></name>
</person-group><article-title>Cutaneous adverse reactions of COVID-19 vaccines: A systematic review</article-title><source>Dermatol. Ther.</source><year>2022</year><volume>35</volume><fpage>e15391</fpage><pub-id pub-id-type="doi">10.1111/dth.15391</pub-id><pub-id pub-id-type="pmid">35194894</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01376"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fink</surname><given-names>A.L.</given-names></name>
<name><surname>Klein</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Sex and Gender Impact Immune Responses to Vaccines Among the Elderly</article-title><source>Physiology</source><year>2015</year><volume>30</volume><fpage>408</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1152/physiol.00035.2015</pub-id><pub-id pub-id-type="pmid">26525340</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01376"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>E.</given-names></name>
<name><surname>Dai</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Fang</surname><given-names>Q.</given-names></name>
</person-group><article-title>Study on the current situation and influencing factors of herpes zoster vaccine hesitation among elderly in Shanghai</article-title><source>Chin. Prev. Med.</source><year>2024</year><volume>25</volume><fpage>222</fpage><lpage>227</lpage></element-citation></ref><ref id="B28-vaccines-12-01376"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cunningham</surname><given-names>A.</given-names></name>
<name><surname>Lal</surname><given-names>H.</given-names></name>
<name><surname>Kovac</surname><given-names>M.</given-names></name>
<name><surname>Chlibek</surname><given-names>R.</given-names></name>
<name><surname>Hwang</surname><given-names>S.</given-names></name>
<name><surname>D&#x000ed;ez-Domingo</surname><given-names>J.</given-names></name>
<name><surname>Godeaux</surname><given-names>O.</given-names></name>
<name><surname>Levin</surname><given-names>M.</given-names></name>
<name><surname>McElhaney</surname><given-names>J.</given-names></name>
<name><surname>Puig-Barber&#x000e0;</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>1019</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1603800</pub-id><pub-id pub-id-type="pmid">27626517</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01376"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lal</surname><given-names>H.</given-names></name>
<name><surname>Cunningham</surname><given-names>A.</given-names></name>
<name><surname>Godeaux</surname><given-names>O.</given-names></name>
<name><surname>Chlibek</surname><given-names>R.</given-names></name>
<name><surname>Diez-Domingo</surname><given-names>J.</given-names></name>
<name><surname>Hwang</surname><given-names>S.J.</given-names></name>
<name><surname>Levin</surname><given-names>M.</given-names></name>
<name><surname>McElhaney</surname><given-names>J.</given-names></name>
<name><surname>Poder</surname><given-names>A.</given-names></name>
<name><surname>Puig-Barber&#x000e0;</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>2087</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1501184</pub-id><pub-id pub-id-type="pmid">25916341</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01376"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ocran-Appiah</surname><given-names>J.</given-names></name>
<name><surname>Boutry</surname><given-names>C.</given-names></name>
<name><surname>Herv&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>Soni</surname><given-names>J.</given-names></name>
<name><surname>Schuind</surname><given-names>A.</given-names></name>
</person-group><article-title>Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.10.029</pub-id><pub-id pub-id-type="pmid">33277059</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01376"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cunningham</surname><given-names>A.</given-names></name>
<name><surname>Sandgren</surname><given-names>K.</given-names></name>
<name><surname>Truong</surname><given-names>N.</given-names></name>
</person-group><article-title>Advances in understanding the mechanism of action of adult vaccines</article-title><source>J. Clin. Investig.</source><year>2023</year><volume>133</volume><fpage>e175378</fpage><pub-id pub-id-type="doi">10.1172/JCI175378</pub-id><pub-id pub-id-type="pmid">38038131</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01376"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>R.</given-names></name>
<name><surname>Fu</surname><given-names>S.</given-names></name>
</person-group><article-title>Research Progress on adjuvavants for human vaccines</article-title><source>Prog. Microbiol. Immunol.</source><year>2024</year><volume>52</volume><fpage>74</fpage><lpage>81</lpage></element-citation></ref><ref id="B33-vaccines-12-01376"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alving</surname><given-names>C.</given-names></name>
<name><surname>Rao</surname><given-names>M.</given-names></name>
<name><surname>Matyas</surname><given-names>G.</given-names></name>
</person-group><article-title>Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1102524</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1102524</pub-id><pub-id pub-id-type="pmid">36761767</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01376"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Xu</surname><given-names>D.</given-names></name>
<name><surname>Ye</surname><given-names>J.</given-names></name>
<name><surname>Xiao</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
</person-group><article-title>Study on surveillance data of adverse events following immunization of seasonal influenza vaccine in China during 2015&#x02013;2018 influenza season</article-title><source>Chin. J. Prev. Med.</source><year>2019</year><volume>53</volume><fpage>E35</fpage><lpage>E37</lpage></element-citation></ref><ref id="B35-vaccines-12-01376"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Susanto</surname><given-names>A.</given-names></name>
<name><surname>Yusman</surname><given-names>F.</given-names></name>
<name><surname>Wati</surname><given-names>F.</given-names></name>
<name><surname>Pratama</surname><given-names>Y.</given-names></name>
</person-group><article-title>Vitamin D3 and Tonsillectomy as Therapeutic Management in Henoch-Sch&#x000f6;nlein Purpura Following Hepatitis B Vaccination: A Rare Case Report</article-title><source>Acta Med. Indones.</source><year>2024</year><volume>56</volume><fpage>987</fpage><lpage>992</lpage></element-citation></ref><ref id="B36-vaccines-12-01376"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tepp</surname><given-names>J.</given-names></name>
<name><surname>Husain</surname><given-names>S.</given-names></name>
<name><surname>Paragh</surname><given-names>L.</given-names></name>
<name><surname>Levit</surname><given-names>E.</given-names></name>
</person-group><article-title>Anti-Smith and Anti-Double-Stranded DNA Antibodies in a Patient with Henoch-Sch&#x000f6;nlein Purpura Following COVID-19 Vaccination</article-title><source>Cutis</source><year>2024</year><volume>114</volume><fpage>E35</fpage><lpage>E37</lpage><pub-id pub-id-type="doi">10.12788/cutis.1062</pub-id><pub-id pub-id-type="pmid">39159358</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01376"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reaila</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
</person-group><article-title>Research advances in the etiology and pathogenesis of immunoglobulin A vasculitis</article-title><source>Chin. J. Contemp. Pediatr.</source><year>2023</year><volume>25</volume><fpage>1287</fpage><lpage>1292</lpage></element-citation></ref><ref id="B38-vaccines-12-01376"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Felicetti</surname><given-names>P.</given-names></name>
<name><surname>Trotta</surname><given-names>F.</given-names></name>
<name><surname>Bonetto</surname><given-names>C.</given-names></name>
<name><surname>Santuccio</surname><given-names>C.</given-names></name>
<name><surname>Brauchli Pernus</surname><given-names>Y.</given-names></name>
<name><surname>Burgner</surname><given-names>D.</given-names></name>
<name><surname>Chandler</surname><given-names>R.</given-names></name>
<name><surname>Girolomoni</surname><given-names>G.</given-names></name>
<name><surname>Hadden</surname><given-names>R.</given-names></name>
<name><surname>Kochhar</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>6634</fpage><lpage>6640</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.027</pub-id><pub-id pub-id-type="pmid">26392009</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01376-f001"><label>Figure 1</label><caption><p>Number of adverse events following immunization cases and reporting rate (per 10,000 doses) associated with recombinant zoster vaccine between 2020 and 2023 in Hangzhou, China.</p></caption><graphic xlink:href="vaccines-12-01376-g001" position="float"/></fig><table-wrap position="float" id="vaccines-12-01376-t001"><object-id pub-id-type="pii">vaccines-12-01376-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic characteristics of vaccination and adverse events following immunization cases following recombinant zoster vaccine in Hangzhou, China.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of<break/>Total Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of<break/>AEFI Case</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reporting Rate (per 10,000 Doses)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003c7;<sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Year</td><td colspan="2" align="center" valign="middle" rowspan="1">2020</td><td align="center" valign="middle" rowspan="1" colspan="1">1755</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">102.56 </td><td align="center" valign="middle" rowspan="1" colspan="1">5.10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td></tr><tr><td colspan="2" align="center" valign="middle" rowspan="1">2021</td><td align="center" valign="middle" rowspan="1" colspan="1">5919</td><td align="center" valign="middle" rowspan="1" colspan="1">46</td><td align="center" valign="middle" rowspan="1" colspan="1">77.72 </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="center" valign="middle" rowspan="1">2022</td><td align="center" valign="middle" rowspan="1" colspan="1">13,646</td><td align="center" valign="middle" rowspan="1" colspan="1">88</td><td align="center" valign="middle" rowspan="1" colspan="1">64.49 </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,759</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83.34 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Age (Y)</td><td colspan="2" align="center" valign="middle" rowspan="1">50&#x02013;59</td><td align="center" valign="middle" rowspan="1" colspan="1">19,208</td><td align="center" valign="middle" rowspan="1" colspan="1">170</td><td align="center" valign="middle" rowspan="1" colspan="1">88.50 </td><td align="center" valign="middle" rowspan="1" colspan="1">8.88</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td colspan="2" align="center" valign="middle" rowspan="1">60&#x02013;69</td><td align="center" valign="middle" rowspan="1" colspan="1">13,198</td><td align="center" valign="middle" rowspan="1" colspan="1">86</td><td align="center" valign="middle" rowspan="1" colspan="1">65.16 </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">&#x02265;70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3673</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.73 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="6" align="center" valign="middle" colspan="1">Sex (sorted by <break/>age groups)</td><td rowspan="3" align="center" valign="middle" colspan="1">Male </td><td align="center" valign="middle" rowspan="1" colspan="1">50&#x02013;59 years</td><td align="center" valign="middle" rowspan="1" colspan="1">5305</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">43.36 </td><td align="center" valign="middle" rowspan="1" colspan="1">14.13</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">60&#x02013;69 years</td><td align="center" valign="middle" rowspan="1" colspan="1">4867</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">61.64 </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;70 years</td><td align="center" valign="middle" rowspan="1" colspan="1">1602</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">31.21 </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="3" align="center" valign="middle" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">50&#x02013;59 years</td><td align="center" valign="middle" rowspan="1" colspan="1">13,903</td><td align="center" valign="middle" rowspan="1" colspan="1">145</td><td align="center" valign="middle" rowspan="1" colspan="1">104.29 </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">60&#x02013;69 years</td><td align="center" valign="middle" rowspan="1" colspan="1">8331</td><td align="center" valign="middle" rowspan="1" colspan="1">57</td><td align="center" valign="middle" rowspan="1" colspan="1">68.42 </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;70 years</td><td align="center" valign="middle" rowspan="1" colspan="1">2071</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">72.43 </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Dose number</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">1</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">19,790</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">211</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">106.62 </td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">53.55</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16,289</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.29 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Residential area</td><td colspan="2" align="center" valign="middle" rowspan="1">central city</td><td align="center" valign="middle" rowspan="1" colspan="1">23,626</td><td align="center" valign="middle" rowspan="1" colspan="1">191</td><td align="center" valign="middle" rowspan="1" colspan="1">80.84 </td><td align="center" valign="middle" rowspan="1" colspan="1">20.28</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td colspan="2" align="center" valign="middle" rowspan="1">suburbs</td><td align="center" valign="middle" rowspan="1" colspan="1">9231</td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">42.25 </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">rural areas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3222</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">139.66 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36,079</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">275</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>AEFI, adverse events following immunization; <italic toggle="yes">p</italic> &#x02264; 0.05; &#x003c7;<sup><sc>2</sc></sup>, Chi-square.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01376-t002"><object-id pub-id-type="pii">vaccines-12-01376-t002_Table 2</object-id><label>Table 2</label><caption><p>Classification of characteristics associated with adverse events following immunization cases related to recombinant zoster vaccine in Hangzhou, China (N = 275).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of <break/>AEFI Case</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Percentage<break/>(%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reporting Rate (per 10,000 Doses)</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cause-specific classification</td><td align="center" valign="middle" rowspan="1" colspan="1">Vaccine product-related reaction</td><td align="center" valign="middle" rowspan="1" colspan="1">272</td><td align="center" valign="middle" rowspan="1" colspan="1">98.91 </td><td align="center" valign="middle" rowspan="1" colspan="1">75.39 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coincidental event</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83 </td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Initial reporting source</td><td align="center" valign="middle" rowspan="1" colspan="1">Vaccination clinic</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">2.55 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.94 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine recipient/their guardian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.45 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.28 </td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Time interval of AEFI occurrence (days)</td><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;1</td><td align="center" valign="middle" rowspan="1" colspan="1">257</td><td align="center" valign="middle" rowspan="1" colspan="1">93.45 </td><td align="center" valign="middle" rowspan="1" colspan="1">71.23 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2&#x02013;3</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">4.00 </td><td align="center" valign="middle" rowspan="1" colspan="1">3.05 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02013;7</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.28 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8&#x02013;14</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.83 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">275</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.22</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01376-t003"><object-id pub-id-type="pii">vaccines-12-01376-t003_Table 3</object-id><label>Table 3</label><caption><p>Clinical diagnosis of adverse events after immunization cases associated with recombinant zoster vaccine in Hangzhou, China (N = 275).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Clinical Diagnosis</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Number of AEFI Cases</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Product-<break/>Related Reaction</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coincidental <break/>Event</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reporting Rate (per <break/>10,000 Doses)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ROR-1.96SE *</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fever (&#x000b0;C)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">37.5&#x02013;38.5</td><td align="center" valign="middle" rowspan="1" colspan="1">123</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">34.09 </td><td align="center" valign="middle" rowspan="1" colspan="1">6.09 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Injection site reaction<break/>(cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;38.6</td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">10.81 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.78 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02264;2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3.05 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.34 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6&#x02013;5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">45</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">12.47 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.54 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">7.48 </td><td align="center" valign="middle" rowspan="1" colspan="1">2.57 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rash</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Allergic</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.22 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.82 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pain <sup>#</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.66 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.86 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fatigue</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2.49 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HSP <sup>##</sup> (serious case)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.28 </td><td align="center" valign="middle" rowspan="1" colspan="1">2.73 **</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gastrointestinal reactions</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.32 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Swelling</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55 </td><td align="center" valign="middle" rowspan="1" colspan="1">5.02 ** </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neurological reactions</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.57 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cardiovascular disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94 </td></tr></tbody></table><table-wrap-foot><fn><p>* ROR: reporting odds ratio, SE: standard error. ** Positive signal. <sup>#</sup> This may include other types of pain, such as muscle and joint pain, as well as pain at the injection site with no other symptoms. <sup>##</sup> HSP: Henoch&#x02013;Sch&#x000f6;nlein purpura.</p></fn></table-wrap-foot></table-wrap></floats-group></article>